b'The FIRST and ONLY FDA-approved intravesical non-replicating gene therapy for high-risk non-muscle invasive bladder cancer (NMIBC)1,2Covered on theVA National Formulary * and 3listed on VA Clinical Pathways VA National VA Clinical 4Formulary PathwaysINDICATION LEARN MORE AT ADSTILADRIN (nadofarageneradenovec-vncg) is aadstiladrinHCP.comnon-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Gu rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product. WARNINGS AND PRECAUTIONS: Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunode cient may beat risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunode cient individuals.DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use e ective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use e ective contraception during ADSTILADRIN treatment and for 3 months after the last dose. ADVERSE REACTIONS: The most common (10%) adverse reactions, including laboratory abnormalities (15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination). You are encouraged to report negative side e ects of prescription drugs to FDA. Visit www.FDA.gov/medwatchor call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.Please see brief summary of Prescribing Information on the following page and full Prescribing Information at adstiladrinHCP.com*Local prior authorization is required.3References: 1. Ferring receives approval from US FDA for Adstiladrin for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Ferring Pharmaceuticals.December 16, 2022. Accessed September 25, 2024. https://www.ferring.com/ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2. Adstiladrin [package insert]. Ferring Pharmaceuticals, Inc; 2024. 3. Nadofarageneradenovec-vncg inj, susp. VA Formulary Advisor.Accessed September 25, 2024. https://www.va.gov/formularyadvisor/drugs/4042650-NADOFARAGENE-FIRADENOVEC-VNCG-INJ-SUSP 4. Veterans A airs. Clinicalpathways. Accessed September 25, 2024. https://www.cancer.va.gov/assets/pdf/clinical-pathways/16/BCCP.pdf2024 Ferring. ADSTILADRIN, Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring. US-ADST-2400226v110/24'